Delivery Order SPE2DB22D2007-SPE2DB25FJ0AU

Award Date 3/20/25
Potential Completion Date 3/21/25
Potential Value $1.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,915.95 firm-fixed-price delivery order is for the supply of Telmisartan 80 mg tablets. It is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,364.08 firm fixed-price delivery order is for the supply of Telmisartan 80 mg tablets. The contract has an ultimate completion date of November 15, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award, with ID SPE2DB20D3304|SPE2DB25FW5C3, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,495.59, is a Delivery Order for the supply of Telmisartan 80 mg tablets. It is a Firm Fixed Price contract with an Ultimate Completion Date of January 16, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $4,079.05, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of Telmisartan 80 mg tablets, a cardiovascular medication. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between Amerisourcebergen and the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,542.77, is a Delivery Order for the supply of Telmisartan 80 mg tablets. The contract has an ultimate completion date of December 31, 2024 and is a Firm Fixed Price contract. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award, valued at $3,663.02, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Telmisartan 80 mg Tablets in quantities of 30s. This contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,884.72 delivery order contract is for the supply of Telmisartan 80 mg tablets to support military healthcare programs. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen also holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, to deliver Telmisartan 80 mg tablets. The $2,277.04 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) the company holds with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,773.16 firm-fixed-price delivery order is for the supply of 4566949024 - Telmisartan 80 mg Tablets in 30-count packages. The contract has an ultimate completion date of January 16, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,444.40 firm-fixed-price delivery order is for the supply of Telmisartan 80 mg tablets, with a completion date of October 21, 2024. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB25FJ0AU
    Delivery Order

This federal contract award, with ID SPE2DB22D2007|SPE2DB25FJ0AU, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,313.10, is for the delivery of Telmisartan 80 mg tablets.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The contract award was not designated with any set-aside requirements, indicating open competition.

Generated 6/19/25, 10:01 AM